Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 218

Glycomic Tumor Neoantigen Discovery in Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse intrinsic pontine glioma (DIPG) is a horrific childhood brain cancer. Patients die within 2 years of diagnosis. Treatments include radio- and chemotherapy, however the tumor always regrows due to resistance of the tumor cells to therapy. Understanding and tackling resistance is key to improve survival of patients with DIPG. We ...

A novel CRISPR/Cas9 approach to target the EWS-FLI1 fusion ...

Ewing’s sarcoma (EWS) is a devastating pediatric cancer of bone and soft tissues where the treatments used are typically very toxic, resulting in profound morbidities. Furthermore, these intense and non-specific treatments often lead to secondary tumors later in life. Thus, a less toxic and more specific treatment is ...

Interaction of Immune System with Oncolytic Measles Virus Therapy of ...

Medulloblastoma (MB) is the most common malignant brain tumor in children. The Group 3 MB patients have the worst prognosis and dismal 5-year survival rate among the four distinct subtypes of MB: WNT, SHH, Group 3 and Group 4 tumors. Sadly, MB survivors face life-long debilitating neurocognitive side effects from craniospinal radiation that ...

Multi-modal Epigenetic Pt(IV) Prodrugs for Paediatric High Grade Gliomas

Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive cancers - DIPG has a survival rate of 1% at 5 years. Platinum(II) anti-cancer drugs (e.g. carboplatin) are used in combination with sodium valproate to treat DIPG clinically, with the intact blood brain barrier being effectively bypassed by convection enhanced delivery. We ...

Defining the molecular mechanisms of DIPG development and progression to ...

  Diffuse Intrinsic Pontine Gliomas (DIPGs) are devastating pediatric brainstem tumors that lack effective treatment and are uniformly fatal. Patient studies have identified recurrent genetic lesions that drive the development of these tumors. Almost all DIPGs carry mutations in genes encoding either replication-dependent histone-H3 proteins (mostly HIST1H3B) or ...